LNAI — Lunai Bioworks Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1527728 ·
Last close
$1.94
Market Cap
$8.80M
52W High
$5.02
52W Low
$1.75
ADV30
136,983
Next earnings
2026-09-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 20,942 | 20,942 | -1,427,260 | -2,571,394 | 9,860,540 | 3,155,272 | 19,413,968 |
| Dec 2025 | 0 | — | -1,823,414 | -1,799,404 | 6,666,446 | 491,645 | 20,215,234 |
| Sep 2025 | 0 | — | -2,476,445 | 2,819,021 | 6,960,663 | 624,808 | 20,001,437 |
| Jun 2025 | 0 | — | -4,113,941 | -126,732,236 | 8,230,840 | 92,700 | 29,580,681 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,258,315
Investing CF
$1,507,851
Financing CF
$6,175,226
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.40
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-512,014,347
Inventory
—
Receivables
$0
ST Investments
$0
EBIT TTM
$-126,637,943
Pretax Income TTM
$-127,197,897
Interest Exp TTM
$559,954
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$20,942
EBITDA
$-9,769,810
Free Cash Flow
$-6,964,201
Enterprise Value
$7,051,841
Total Cash
$3,155,272
Total Debt
$1,411,367
Shares Out
4,533,890
Trailing EPS
$-61.52
Book Value
$-2.14
ROE
-325.5%
ROA
-9.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 0 | -18,546,573 | -178,007,489 | 8,230,840 | 29,580,681 | — | -7,874,647 |
| Jun 2024 | 0 | -27,388,296 | -88,425,828 | 163,129,450 | 31,152,306 | — | -10,971,430 |
| Jun 2023 | 0 | -19,596,891 | -39,684,056 | 58,300,796 | 11,798,685 | — | -11,774,549 |
| Jun 2022 | 0 | -22,826,191 | -113,433,392 | 84,632,663 | 12,013,815 | — | -15,732,336 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMRN | Immuron Ltd | $8.80M | $1.09 | — |
| QNRX | Quoin Pharmaceuticals, Ltd. | $8.94M | $4.45 | — |
| LSTA | LISATA THERAPEUTICS, INC. | $9.02M | $0.99 | — |
| CNSP | CNS Pharmaceuticals, Inc. | $8.50M | $5.82 | — |
| ASBP | Aspire Biopharma Holdings, Inc. | $8.44M | $6.52 | — |
News headlines (Yahoo Finance, 1h cache)
LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS
2026-06-17 13:15 · Yahoo
Why Did LNAI Stock Soar Over 100% In Pre-Market Trading Today?
2026-06-17 10:30 · Yahoo
Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration
2026-05-28 13:15 · Yahoo
LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT
2026-05-20 13:15 · Yahoo
Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer’s Disease
2026-05-06 12:30 · Yahoo
Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP
2026-05-04 13:35 · Yahoo
Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships
2026-04-15 13:10 · Yahoo
Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion
2026-04-07 13:05 · Yahoo
BC-Most Active Stocks
2026-03-26 14:30 · Yahoo
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications
2026-03-26 12:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.